Evidence map›Paper›PMID 28810904›Full record

ArticleScandinavian journal of trauma, resuscitation and emergency medicine2017

Antiarrhythmic drug therapy among patients presenting to emergency department with symptomatic atrial fibrillation - a prospective nationwide cohort.

Tero Penttilä, Heikki Mäkynen, Juha Hartikainen, Harri Hyppölä, Timo Lauri, Mika Lehto, Juha Lund, M J Pekka Raatikainen, FinFib2 investigators

Registry-linked trialAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Scandinavian journal of trauma, resuscitation and emergency medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01990105 (Treatment of Atrial Fibrillation in Finland - the FinFib 2 Study), which is not on this map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01990105 completednot on this map

Treatment of Atrial Fibrillation in Finland - the FinFib 2 Study

TypeobservationalSponsorFinnish Cardiac SocietyRan2013 to 2014Enrolled1,013ConditionsAtrial Fibrillation
3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Tero PenttiläHeart Center Co. Tampere University Hospital, P.O. Box 2000, -33521, Tampere, FI, Finland. tero.penttila@sydansairaala.fi.
Heikki MäkynenHeart Center Co. Tampere University Hospital, P.O. Box 2000, -33521, Tampere, FI, Finland.
Juha HartikainenHeart Center, Kuopio University Hospital, Kuopio, Finland.
Harri HyppöläEmergency Department, Kuopio University Hospital, Kuopio, Finland.
Timo LauriOulu University Hospital, Oulu, Finland.
Mika LehtoHeart and Lung Center, Helsinki University Hospital, Helsinki, Finland.
Juha LundTurku University Hospital, Turku, Finland.
M J Pekka RaatikainenHeart and Lung Center, Helsinki University Hospital, Helsinki, Finland.
FinFib2 investigators

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAtrial fibrillation (AF) is a common arrhythmia that causes numerous visits to emergency departments (ED). The aim of the FinFib2 study was to evaluate whether treatment of patients with AF in ED is consistent with the contemporary European Society of Cardiology (ESC) management guidelines. Here we report the results of antiarrhythmic drug therapy (AAD) in ED.

methodsAll patients within the two-week study period whose primary reason for the ED visit was symptomatic AF were included into this prospective multicentre study. Comprehensive data on factors contributing to the treatment of AF were collected, including a data of previous use of ADDs, and changes made for them during a visit in ED.

resultsThe study population consisted of 1013 consecutive patients (mean age 70 ± 13 years, 47.6% female). The mean European Heart Rhythm Association (EHRA) symptom score was 2.2 ± 0.8. Rhythm control strategy was opt for 498 (63.8%) and 140 (64.5%) patients with previously and newly diagnosed AF, respectively. In patients with previously diagnosed AF the most frequently used AAD was a beta blocker (80.9%). Prior use of class I (11.4%) and III (9.1%) AADs as well as start or adjustment of their dosage (7.4%) were uncommon. Most of the patients with newly diagnosed AF were prescribed a beta blocker (71.0%) or a calcium channel antagonist (24.0%), and only two of them received class I or class III AADs.

conclusionsOur data demonstrated that in patients presenting to the ED with recurrent symptomatic AF and aimed for rhythm control strategy, the use of class I and class III AADs was rare despite ESC guideline recommendations. It is possible that early adaptation of a more aggressive rhythm control strategy might improve a quality of life for symptomatic patients and alleviate the ED burden associated with AF. Beta blockers were used by majority of patients as rate control therapy both in rate and rhythm control groups.

trial registrationNCT01990105 . Registered 15 November 2013.

Indexed as

Emergency Service, HospitalAdrenergic beta-AntagonistsAdultAgedAged, 80 and overAnti-Arrhythmia AgentsAtrial FibrillationFemaleFinlandGuideline AdherenceHumansMaleMiddle AgedPractice Guidelines as TopicProspective StudiesYoung AdultAdrenergic beta-AntagonistsAnti-Arrhythmia AgentsAntiarrhythmic medicationAtrial fibrillationEHRA scoreEmergency departmentRate controlRhythm control

Identifiers

PMID28810904
PMCPMC5558694

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.